GLOBALHealthPR
Global Health Marketing and Communications (GHMC) welcomes Improve Comunicaciones as an exclusive agency partner in Mexico, strengthening network’s capabilities in Latin America
As the exclusive Australian partner of Global Health Marketing and Communications (GHMC) – the largest and most robust network of independent healthcare agencies worldwide – VIVA! Communications extends a warm welcome to our newest member – Improve Comunicaciones. The addition of the Mexican-based, strategic consulting agency to GHMC, strengthens our GHMC network’s offering, and capabilities…
Read MoreLooking back on my time at VIVA! – Bella Poidevin
When I first came to VIVA! offices in December, 2017 to meet a woman named Kirsten Bruce for a job interview, I could never have imagined the journey that was about to begin. Starting in the VIVA! office with no prior communications experience, but a (somewhat over the top) passion for healthcare, made for a…
Read MoreVIVA! appoints Julia Slater as GM
VIVA! Communications (VIVA!) has today announced the appointment of Julia Slater as General Manager (GM) of the award-winning, independent, Australian health + wellness communications agency and Asia Pacific hub lead for GLOBALHealthPR. Julia brings more than a decade of PR and communications experience to her new role, to support VIVA!’s recent, unparalleled local and international…
Read MoreAussies with CVD at higher risk from COVID-19
Tracking the incidence of COVID-19 globally, it is understood that people over the age of 60 with a pre-existing chronic condition, such as cardiovascular disease (CVD) or diabetes, are considered at greater risk to serious infection and complications.1 There has been a high prevalence of CVD in those dying from COVID-19 in Italy and China, two of the worst…
Read MoreAussies & Kiwis with incurable blood cancer receive newly subsidised treatment option
Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…
Read More